These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rivaroxaban-induced liver injury: Results from a venous thromboembolism registry. Lambert A; Cordeanu M; Gaertner S; Nouri S; Alt M; Stephan D Int J Cardiol; 2015 Jul; 191():265-6. PubMed ID: 25981364 [No Abstract] [Full Text] [Related]
7. New oral anticoagulants (NOAC) and liver injury. Moore N; Blin P; Gulmez SE J Hepatol; 2014 Aug; 61(2):198-9. PubMed ID: 24837361 [No Abstract] [Full Text] [Related]
8. Liver injury during rivaroxaban treatment in a patient with AL amyloidosis. Marrinan A; Shackleton L; Kelly C; Lavin M; Glavey S; Murphy P; Quinn J Eur J Clin Pharmacol; 2021 Jul; 77(7):1073-1076. PubMed ID: 33427957 [No Abstract] [Full Text] [Related]
9. Use of apixaban after development of suspected rivaroxaban-induced hepatic steatosis; a case report. Anastasia EJ; Rosenstein RS; Bergsman JA; Parra D Blood Coagul Fibrinolysis; 2015 Sep; 26(6):699-702. PubMed ID: 26154612 [TBL] [Abstract][Full Text] [Related]
10. Prothrombin complex concentrate administration through intraosseous access for reversal of rivaroxaban. Means L; Gimbar RP Am J Emerg Med; 2016 Mar; 34(3):685.e1-2. PubMed ID: 26403851 [No Abstract] [Full Text] [Related]
11. Epistaxis complicated by rivaroxaban managed with topical tranexamic acid. Utkewicz MD; Brunetti L; Awad NI Am J Emerg Med; 2015 Sep; 33(9):1329.e5-7. PubMed ID: 25895714 [No Abstract] [Full Text] [Related]